PTN
$9.36
$-0.64 (-6.40%)-6.40%
ClosedLoading chart...
IndexN/A
Market Cap0.02B
Enterprise Value0.00B
Income$-0.02B
Sales$0.00B
EmployeesN/A
P/E85.09
P/S0.00
P/B-0.79
P/C-0.18
EV/EBITDA-0.08
EV/SalesN/A
EPS (ttm)0.11
EarningsN/A
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Volume0.01M
Shs Outstand0.00B
Change-6.40%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $4.49M | $4.85M | $1.47M | $-188.60K | $117.99K | $60.30M | $67.13M |
| Cost of Revenue | $258.92K | $97.64K | $418.47K | $217.53K | $147.84K | $0.00 | $14.86M | $32.57M |
| Gross Profit | $-258.92K | $4.39M | $4.44M | $1.25M | $-336.44K | $117.99K | $45.44M | $34.57M |
| Gross Margin | N/A | 97.83% | 91.38% | 85.19% | 178.39% | 100.00% | 75.36% | 51.49% |
| Operating Expenses | $22.45M | $26.89M | $36.89M | $37.84M | $33.05M | $23.72M | $9.70M | $8.64M |
| Operating Income | $-22.71M | $-22.50M | $-32.46M | $-36.59M | $-33.38M | $-23.61M | $35.74M | $25.93M |
| Operating Margin | N/A | -501.02% | -668.75% | -2491.63% | 17701.29% | -20007.61% | 59.28% | 38.62% |
| Net Income | $-17.31M | $-29.74M | $-24.04M | $-36.20M | $-33.57M | $-22.43M | $35.77M | $24.70M |
| Net Margin | N/A | -662.26% | -495.23% | -2465.06% | 17799.23% | -19006.88% | 59.32% | 36.80% |
| EPS (Basic) | $-32.15 | $-2.02 | $-2.21 | $-3.79 | $-3.55 | $-2.38 | $4.31 | $3.12 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $3.27M | $10.74M | $17.94M | $36.07M | $67.30M | $85.05M | $104.74M | $39.02M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $8.04M | $10.85M | $19.92M | $19.80M | $17.65M | $4.88M | $4.19M | $12.05M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $-4.78M | $-111.50K | $-1.98M | $16.27M | $49.65M | $80.17M | $100.55M | $26.96M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $-4.78M | $-111.50K | $-1.98M | $16.27M | $49.65M | $80.17M | $100.55M | $26.96M |
| Total Liabilities & Stockholders Equity | $3.27M | $10.74M | $17.94M | $36.07M | $67.30M | $85.05M | $104.74M | $39.02M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $-17.31M | $-29.74M | $-24.04M | $-36.20M | $-33.57M | $-22.43M | $35.77M | $24.70M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $-21.31M | $-31.46M | $-28.42M | $-29.92M | $-22.65M | $41.33M | $-21.78M | $1.70M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Why Are Palatin Technologies (PTN) Shares Spiking After-Hours?Benzinga Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025Benzinga Data la crescita esponenziale del settore del turismo in Arabia Saudita, dmg events annuncia il salone Hotel & Hospitality ExpoGlobeNewswire Inc. As Saudi Arabia’s Tourism Sector Grows Exponentially, dmg events Announces Hotel & Hospitality ExpoGlobeNewswire Inc. Palatin Technologies (PTN) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research Palatin Technologies And 2 Other Stocks Under $3 Insiders Are BuyingBenzinga Palatin (PTN) Up 15% on Results From Dry Eye Disease StudyZacks Investment Research Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionBenzinga
Show 12 more stories
Dow Dips 200 Points; TJX Posts Upbeat SalesBenzinga Strength Seen in Repligen (RGEN): Can Its 4.3% Jump Turn into More Strength?Zacks Investment Research Why Getaround Shares Are Trading Higher By Around 86%; Here Are 20 Stocks Moving PremarketBenzinga Kronos Bio, Inc. (KRON) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day SessionBenzinga Palatin Technologies, Inc. (PTN) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research Alimera Sciences (ALIM) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research TELA Bio, Inc. (TELA) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research Guardant Health (GH) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research Myovant Sciences (MYOV) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research Palatin Technologies, Inc. (PTN) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research Solid Biosciences Inc. (SLDB) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
Discover more
You may be interested in